Clinical and Preclinical Systematic Review of *Panax ginseng* C. A. Mey and Its Compounds for Fatigue

**Ting-Yu Jin, Pei-Qing Rong, Hai-Yong Liang, Pei-Pei Zhang, Guo-Qing Zheng* and Yan Lin***

Department of Neurology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou, China

**Background:** Fatigue, as a complex, multidimensional symptom, is associated with many physical illnesses. *Panax ginseng* C. A. Mey (PG) is an important herbal drug which has been used for benefiting Qi for thousand years. *Panax ginseng* C. A. Mey and its compounds (PGC) possess various pharmacological activities, including anti-fatigue. Here, we conducted a systematic review of both randomized clinical trials (RCTs) and preclinical animal studies to investigate the efficacy and safety of PGC for fatigue.

**Methods:** Electronic searches were performed in 7 databases from the time of each database's inception to August 2019. The methodological quality of RCTs was assessed using 7-item checklist recommended by Cochrane Collaboration or by the CAMARADES 10-item quality checklist. All the data were analyzed using Rev-Man 5.3 and Stata SE software.

**Results:** Eight eligible RCTs and 30 animal studies were identified. The risk of bias scores in RCTs ranged from 4/7 to 7/7, and of animal studies varied from 4/10 to 7/10. Meta-analyses showed that PGC was superior to placebo according to their respective fatigue scales, heart rate recovery, and clinical effect (P < 0.05). There were a similar number of adverse effects between PGC and placebo group (P > 0.05). Meta-analyses showed that PGC can significantly decrease level of blood lactate, blood urea nitrogen, creatine kinase, malondialdehyde, and lactic dehydrogenase in serum, level of malondialdehyde in liver and level of gamma-aminobutyric acid, 5-hydroxytryptamine in brain tissue, and increase swimming time, level of glutathione peroxidase, glucose, superoxide dismutase in serum, level of glycogen and activity of superoxide dismutase, glutathione peroxidase, and catalase in skeletal muscle, level of hepatic glycogen in liver and level of dopamine, acetylcholine in brain tissue, compared with control (P < 0.05). Meta-analyses showed no significant difference in animal body weight between PGC and control (P > 0.05).

**Conclusion:** The present findings supported, to a certain degree, that PGC can be recommended for routine use in fatigue. The possible mechanism of PGC resists fatigue, mainly through antioxidant stress, regulating carbohydrate metabolism, delaying the...
accumulation of metabolites, promoting mitochondrial function, neuroprotection, antiapoptosis, and regulating neurotransmitter disorder in central nervous system.

Keywords: ginseng, fatigue, randomized controlled trials, animal studies, systematic review

INTRODUCTION

Description of the Condition
Fatigue is a condition of lacking the energy and motivation in responding to physical activity, emotional stress, boredom or insufficient sleep (Bach et al., 2016). It is a complex, multidimensional symptom that is prevalent in the general population (Jason et al., 2010). The cause of fatigue is unknown. The severity of fatigue varies greatly among individuals. Although fatigue does not lead to death, it has negative impacts on many areas of daily life (Arring et al., 2018). “Feeling weak all over for much of the time” was regarded as one of the most important symptoms (Lewis and Wessely, 1992). Most physical illnesses are associated with fatigue, such as many chronic diseases, namely anaemia, emphysema, asthma, and arthritis (Chen, 1986). Fatigue is a clinical challenge because its study of etiology, risk factors, and pathophysiology are still at an early stage. The goal of treatment is to treat symptoms and improve outcomes rather than to provide clear treatment (Alraek et al., 2011).

Description of the Intervention
Different interventions have been used in treating fatigue (Whiting et al., 2001). Nowadays, treatments commonly focus on muscle pain, sleep disorders, and emotional symptoms. Cognitive Behavior Therapy (CBT), various forms of exercise, as well as enhancement of coping ability, are standard treatment options. In addition, caregiver prescribed or self-administered medication are still common (Jones et al., 2007). It is indicated that no universal western medicine treatment can be recommended (Collatz et al., 2016). Interventions which include CBT and graded exercise therapy have shown promising results (Whiting et al., 2001). However, patients seem to be skeptical about CBT, who claimed that CBT and graded exercise for fatigue were neither effective nor safe (Twisk and Corsius, 2018). Recently, various forms of complementary and alternative medicine (CAM) have been widely used in fatigue such as herbal medicine, chiropraxis, balanced nutrition, and acupuncture (Jones et al., 2007). In particular, Panax ginseng C.A. Mey (PG) has been a rising utilization in treating fatigue in Asia and elsewhere around world. Based on traditional Chinese medicine and herbal philosophy, PG is considered as an adaptation to help restore body balance (Arring et al., 2018). Panax ginseng C.A. Mey is believed to improve overall quality of life (QoL), including energy and vitality, particularly during times of fatigue or stress (Yennurajalingam et al., 2017).

Why It Is Important to Do This Review
Panax ginseng C.A. Mey is one of the most widely used plant products worldwide which has been used in oriental countries for thousands of years (Zheng et al., 2017). Based on a comprehensive collection of clinical trials, systematic review can perform comprehensive analysis and statistical processing on qualified studies to form relatively reliable results, which can guide clinical decision-making. In addition, systematic review can solve the following clinical problems: research on the effectiveness of treatment, evaluation of diagnostic methods, prognosis estimation, analysis of the cost and benefit of treatment. Up to now, at least 2 systematic reviews have been conducted to evaluate efficacy and safety of Panax ginseng C. A. Mey and its compounds (PGC) for fatigue (Bach et al., 2016; Arring et al., 2018). However, the results of these reviews are inconclusive because of methodological flaws in their included primary studies. Cochrane group have developed an extensive set of guide lines for systematic reviews. These “not-so-good” studies were excluded with a strict process (Xie et al., 2013). In addition, the efficacy and mechanisms of PGC in fatigue animal models have not been systematically evaluated yet. Systematic review of animal researches is indispensable in the process of drug development and elucidation of the physiological and pathological mechanisms (Zheng et al., 2018). Preclinical research is the key to convert preclinical data into clinical data. In addition, systematic review of animal research is a more economic and ethical approach, which can integrate preclinical evidence, help reduce unnecessary sacrifice of laboratory animals, and prevent ineffective or less informative research (Zhou et al., 2019). As we all know, there is a gap between clinical research
and clinical practice. More communication is needed between animal researchers and clinical researchers. Systematic review of animal experiments can lead to better collaboration between research groups and encourage the use of iterative methods to improve the relevance of animal models to clinical trial design. If the model cannot well simulate the clinical situation, it can be adjusted accordingly. In addition, as in human research, systematic review helps to identify and improve behavioral and reporting deficiencies in animal research Perel et al., 2007. Systematic review can effectively integrate preclinical comprehensive evidence and guide potential clinical translation. Thus, the aim of present study was to systematically summarize and critically evaluate the data from randomized control trials (RCTs) and animal studies of PGC for fatigue.

**METHODS**

**Search Strategy**

This study followed the PRISMA statement (Stewart et al., 2015). EMBASE, PubMed, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP database (VIP), China Biology Medicine Database (CBM) and Wangfang database were electronically searched from their inception to August 2019. The following keywords were used: “fatigue OR Lassitude lethargy OR exhaustion OR weariness OR tiredness” and “panax OR Ginseng OR renshen” in Chinese or in English. All searches were limited to animal studies and clinical trials.

**Eligibility Criteria**

The prespecified inclusion criteria of RCTs listed below: (1) RCTs that evaluated the effectiveness and safety of PGC for fatigue; (2) the Cochrane risk of bias (ROB) tool met at least 4 out of the 7 domains; (3) Subjects had chronic fatigue syndrome (CFS) or healthy adults after exercise; Subjects were classified as CFS-like according to Evaluation and Classification of Unexplained Chronic Fatigue (ECUCF) (Fukuda et al., 1994); (4) PGC as monotherapy was used as an intervention in the treatment group, and interventions for control group were placebo or vehicle treatment; (5) The primary outcome measures were scales of fatigue and/or objective evaluation criteria (e.g. physical performance, biochemical parameters). The secondary outcome measures were clinical effect according to fatigue scales and adverse events. The exclusion criteria were prespecified as follows: (1) fatigue caused by a medical condition, or withdrawal from medicines or substance; (2) duplicate publications and no available data. 

The inclusion criteria of animal studies were prespecified as follows: (1) PGC for fatigue animal models was established by forced movement; (2) The interventions of treatment group were PGC at any dose and control group were nonfunctional liquid (normal saline) or no treatment; and (3) The primary outcome measures were forced movement time and/or serum biochemical parameters and/or skeletal muscle biochemical parameters and/or liver biochemical parameters and/or brain tissue biochemical parameters. The secondary outcome measures were body weight, organ index (organ weight/body weight) and possible mechanisms of PGC for anti-fatigue. The exclusion criteria were predefined as follows: (1) not fatigue model; (2) combined use of other drugs; and (3) no available data, duplicate publications, and lack of control group.

**Data Extraction**

Two independent researchers extracted the details from the included RCTs and animal studies according to two standardized data extraction forms, respectively. There are many manners for including outcomes, such as peak time point, last time point, and same time point. There is undeniable that any manner will lead to bias. In order to minimize bias, inclusion criteria were prespecified as follows: The result of the peak time point was included when the data were expressed at different times. If meta-analysis data were lost or expressed graphically, we would try to contact the author for more information. When no response was received, we used digital ruler software or exclusion software to measure data from charts. If the data in the primary RCT were missing or merely illustrated graphically, an effort was launched to obtain further information through contacting the authors. If failed, the digital ruler software was used for measuring data from the graphs or excluded.

**Quality Assessment**

The methodological quality of the included RCTs was evaluated using the Cochrane Collaboration’s tool. The RoB of the included animal studies was assessed using 10-item quality checklist of the Collaborative Approach to Meta-Analysis and Review of Animal Data from Experimental Studies (Camarades) with minor modification. Divergences were well settled by correspondence author (GZ).

**Statistical Analysis**

Analysis was conducted with RevMan 5.3 and Stata SE software. Continuous outcomes were presented as mean difference (MD) or standardized mean difference (SMD) with 95% confidence interval (CI). Dichotomous outcomes were presented risk ratio (RR) or odds ratio (OR) with 95% CI. Probability values P <0.05 were considered significant. In order to estimate heterogeneity across studies, we used I² - statistic test. An I² value greater than 50% was considered as having substantial heterogeneity. When substantial heterogeneity was not observed, the fixed-effects model was reported. On the contrary, the random-effects model was reported. Simultaneously, considering the differences in subjects, interventions, and treatments, we used the Z-test for subgroup analysis. P <0.05 was considered to be statistically significant. If an outcome contained more than 10 RCTs, funnel plots, and Egger's test were used to examine publication bias.

**RESULTS**

**Study Selection**

A total of 1331 relevant literatures were retrieved from the database, of which 667 were considered duplicates. Of the remaining 664 articles, qualified RCTs and animal experiments should be selected separately. For RCTs, 362 articles were
eliminated because of reviews, case report, or animal studies. After scanning the remaining 302 full-text articles, 294 studies were excluded by reasons that they were (1) combined with other disease; (2) combined with other herbal treatment(s) in the intervention group; (3) no data available; (4) not real RCTs or quasi-RCTs; or (5) with the less than 4 domains “yes” according to the Cochrane RoB tool. Eventually, 8 RCTs were selected (Figure 1A). For animal studies, 243 studies including clinical trials, case reports or review articles were excluded. Through full-text evaluation of the remaining 421 studies, 391 were excluded for at least one of the following reasons: (1) lack of control group; (2) inappropriate fatigue model; (3) combined with other herbal treatment(s) in the intervention group; (4) unavailable data. Ultimately, 30 animal studies were included (Figure 1B).

**Study Characteristics**

**Randomized Control Trials**

All involved studies were published in English. All 8 studies (Gal et al., 1996; Engels et al., 1996; Engels et al., 2001; Engels et al., 2003; Hartz et al., 2004; Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) were RCTs, which involved a total of 678 participants, and the sample size ranged from 19 to 218. Five RCTs (Gal et al., 1996; Hartz et al., 2004; Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) involved 615 participants with CFS. The diagnostic criteria of patients with CFS were based on the International Classification of Disease (ICD), and the duration of treatment ranged from 8 to 16 weeks. They were published from 1996 to 2016 and conducted in America (n = 4) (Engels et al., 1996; Engels et al., 2001; Engels et al., 2003; Hartz et al., 2004), South Korea (n = 3) (Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016), and France (n = 1) (Gal et al., 1996). The duration of treatment ranged from 4 to 8 weeks. They used PGC as intervention of experimental group. The placebo-control was used in all 8 studies. Five studies (Engels et al., 1996; Engels et al., 2001; Engels et al., 2003; Hyeong-Geug et al., 2013; Kim et al., 2016) used objective evaluation criteria, including metabolic response and physical performance as outcome measure. Five studies (Gal et al., 1996; Hartz et al., 2004; Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) used self-reported fatigue measures, including Rand Vitality Index (RVI), Mood and Anxiety Symptom Questionnaire (MASQ), fatigue duration, checklist individual strength (CIS), Numeric Scale (NRS), Visual Analogue Scale (VAS), Visual Analogue Fatigue Scale (VAFS), Revised Piper Fatigue Scale (RPFS), Short-Form Health Survey (SF-36), Fatigue score, and clinical effect as outcome measure. The general characteristics of the 8 included articles were illustrated in Tables 1 and 2.

**Animal Studies**

Nine studies (Choi et al., 2011; Hwang et al., 2014; Qi et al., 2014; Wang et al., 2014; Oh et al., 2015; Bao et al., 2016; Ma et al., 2017; Zheng et al., 2017; Delgado et al., 2019) were published in English and 21 studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Gao et al., 2011; Xu et al., 2011; Song et al., 2013; Zhao et al., 2014; Liu et al., 2015; Wang et al., 2015; Liu, 2016; Shi et al., 2016; Yao, 2016) were published in Chinese between 2005 and 2019. All 30 studies involved a total of 2249 animals. Twelve studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Liu, 2016) used Sprague Dawley (SD) rats; 1 study (Song et al., 2013) used Wistar rats; 8 studies (Choi et al., 2011; Hwang et al., 2014; Wang et al., 2014; Oh et al., 2015; Bao et al., 2016; Ma et al., 2017; Zheng et al., 2017; Delgado et al., 2019) used Institute of Cancer Research (ICR) mice; 6 studies (Li et al., 2009; Xu et al., 2011; Zhao et al., 2014; Qi et al., 2014; Wang et al., 2015; Shi et al., 2016) used Kunming (KM) mice; 3 studies (Gao et al., 2011; Liu et al., 2015; Yao, 2016) used unknown breed mice. Twenty-seven studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Gao et al., 2011; Wang et al., 2014; Li et al., 2015; Bao et al., 2016; Ma et al., 2017; Zheng et al., 2017; Delgado et al., 2019) used male animals; 2 studies (Qi et al., 2014; Zhao et al., 2014) used both female and male rats, and 1 study (Xu et al., 2011) did not mention gender of animals. The weight of adult rats varied between 160 and 260 g and mice between 16 and 28 g. Anesthetic was mentioned in 1 study (Chen and Li, 2011). Ginsenosides were used in 18 studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b); 10 studies (Qi et al., 2014; Wang et al., 2014; Oh et al., 2015; Bao et al., 2016; Ma et al., 2017) used ginseng in 6 studies (Choi et al., 2011; Gao et al., 2011; Hwang et al., 2014; Zhao et al., 2014; Shi et al., 2016; Ma et al., 2017), ginseng oligopeptides in 2 studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Xu et al., 2011; Chen and Li, 2011; Hwang et al., 2014; Wang et al., 2015; Shi et al., 2016) by Forced swimming test (FST) and 3 models (Choi et al., 2011; Oh et al., 2015; Shi et al., 2016; Delgado et al., 2019) by Rota-rod test. The non-functional liquid, normal saline or no treatment control was introduced in all 30 studies. Thirteen studies (Li et al., 2009 Xu et al., 2011; Song et al., 2013; Qi et al., 2014; Zhao et al., 2014; Liu et al., 2015; Oh et al., 2015; Wang et al., 2015; Bao et al., 2016; Shi et al., 2016; Yao, 2016; Ma et al., 2017; Delgado et al., 2019) utilized swimming time as outcome measure, and climbing time in 1 study (Shi et al., 2016). Serum biochemical parameters, including BLA, BUN, glucose (GLU),
FIGURE 1 | (A) Flow diagram of randomized control trials selection process. (B) Flow diagram of animal experiments selection process.
creatine kinase (CK), MDA, superoxide dismutase (SOD), glutathione peroxidase (GSH-Px), and LDH were reported in 15 studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Wang et al., 2015; Wang et al., 2015; Bao et al., 2016; Shi et al., 2016; Yao, 2016; Ma et al., 2017; Delgado et al., 2019); skeletal muscle biochemical parameters, including glycogen, MDA, SOD, and GSH-Px in 14 studies (Feng et al., 2009c; Pan et al., 2010a; Gao et al., 2011; Xu et al., 2011; Wang et al., 2014; Zhao et al., 2014; Zhao et al., 2014; Liu et al., 2015; Oh et al., 2015; Wang et al., 2015; Bao et al., 2016; Shi et al., 2016; Yao, 2016; Ma et al., 2017; Delgado et al., 2019); liver biochemical parameters, including glycogen, MDA, SOD, and GSH-Px in 14 studies (Feng et al., 2009c; Pan et al., 2010a; Gao et al., 2011; Xu et al., 2011; Wang et al., 2014; Zhao et al., 2014; Zhao et al., 2014; Liu et al., 2015; Oh et al., 2015; Wang et al., 2015; Bao et al., 2016; Shi et al., 2016; Yao, 2016; Ma et al., 2017; Delgado et al., 2019); brain tissue biochemical parameters, including acetylcholine (ACh), dopamine (DA), gamma-aminobutyric acid (GABA), 5-hydroxytryptamine (5-HT) in 5 studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Chen and Li, 2011; Liu, 2016); and body weight in 7 studies (Li et al., 2009; Xu et al., 2011; Song et al., 2013; Hwang et al., 2014; Bai et al., 2016; Liu, 2016; Shi et al., 2016). Approach to achieving of PGC was reported in 15 studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Choi et al., 2011; Song et al., 2013; Jin et al. Ginseng for Fatigue

**TABLE 1 | Characteristics of the included randomized control trials.**

| First Authors; year | Study design | Gender (male/female); mean/range age(years) | Interventions | Course of treatment | Outcome measure | Intergroup differences |
|---------------------|-------------|------------------------------------------|---------------|---------------------|----------------|-----------------------|
| Engels et al., 1996 | RCT         | 10                                       | G115 (200 mg qd) po placebo 8 weeks | 1. blood lactic acid 1. P > 0.05 |
|                     |             | 21–35                                    |               |                     |                |                       |
|                     |             | 21–35                                    | G115 (400 mg qd) po placebo 8 weeks | 1. peak anaerobic power output 1. P > 0.05 |
|                     |             | 27.1 ± 7.0                               |               |                     |                |                       |
|                     |             | 23.8 ± 5.4                               |               |                     |                |                       |
| Engels et al., 2001 | RCT         | 9                                        | G115 (400 mg qd) po placebo 8 weeks | 1. Peak power output 1. P < 0.01 |
|                     |             | 26.1 ± 1.7                               |               |                     |                |                       |
| Hartz et al., 2004  | RCT         | 30/6                                      | extract of PG (800 mg bid) po placebo 2 months | 1. Fatigue severity 1. P < 0.05 |
|                     |             | 21–34 0                                  |               |                     |                |                       |
|                     |             | 35–49 18                                 |               |                     |                |                       |
|                     |             | 50–65 7                                  |               |                     |                |                       |
| Kim et al., 2016    | RCT         | 23/49                                     | URSA (1# 50 mg bid) po placebo 4 weeks | 1. QIB score 1. P < 0.05 |
|                     |             | < 29 27                                  |               |                     |                |                       |
|                     |             | 30–39 25                                 |               |                     |                |                       |
|                     |             | 40–49 16                                 |               |                     |                |                       |
|                     |             | > 50 4                                   |               |                     |                |                       |
| Hyeong-Geug et al., | RCT         | 21/69                                     | PG (1, 2 g qd) po placebo 4 weeks | 1. MASQ 1. P < 0.05 |
| 2013                |             | 39.5                                     |               |                     |                |                       |
|                     |             | 6/24                                      |               |                     |                |                       |
|                     |             | 39.5                                     |               |                     |                |                       |
| Lee et al., 2016    | RCT         | 5/21                                      | EMGE (500 mg bid) po placebo 4 weeks | 1. VAFS 1. P < 0.01 |
|                     |             | 60.1 ± 4.44                              |               |                     |                |                       |
|                     |             | 7/19                                      |               |                     |                |                       |
|                     |             | 62.1 ± 5.18                              |               |                     |                |                       |
|                     |             | 5.18                                      |               |                     |                |                       |
| Gal et al., 1996    | RCT         | 34/75                                     | Pharmaton Capsule (1# bid) placebo 42 days | 1. Fatigue score 1. P < 0.01 |
|                     |             | 37.6                                      |               |                     |                |                       |
|                     |             | 34/75                                    |               |                     |                |                       |

**Table Footnotes:** ALT, alanine aminotransferase; AST, aspartate aminotransferase; CIS, checklist individual strength; GSH, glutathione; GSH-Rd, glutathione reductase; G115, standardized P. ginseng C.A. Mey concentrate; MASQ, Mood and Anxiety Symptom Questionnaire; MDA, malondialdehyde; NRS, self-rating numeric scale; PG, P. ginseng C.A. Mey; RER, respiratory exchange ratio; ROS, reactive oxygen species; RPFS, Revised Piper Fatigue Scale; RVI, Rand Vitality Index; SF-36, Short-Form Health Survey; VAS, visual analog scale; VAFS, visual analog fatigue scale; VE, minute ventilation.
Hwang et al., 2014; Wang et al., 2014; Liu et al., 2015; Oh et al., 2015; Wang et al., 2015; Bao et al., 2016; Liu, 2016; Shi et al., 2016; Zheng et al., 2017; Delgado et al., 2019) and quality control of PGC was reported in 8 studies (Feng et al., 2009a; Feng et al., 2010a; Chen and Li, 2011; Wang et al., 2014; Liu et al., 2015; Oh et al., 2015; Zheng et al., 2017; Delgado et al., 2019). Tables 3 and 4 show the characteristics of included publications.

**Study Quality**

**Randomized Clinical Trials**

Table 5 illustrates the methodological quality of 8 RCTs based on the Cochrane Collaboration's tool. All of them were ranged from 4 to 7 points. All included studies reported the method of random sequences generation, the criteria of a double-blind study design, and taking the complete outcome data into account. Three studies (Hartz et al., 2004; Hyeong-Geug et al., 2013; Lee et al., 2016) reported using allocation concealment. Two studies (Hartz et al., 2004; Lee et al., 2016) applied blinding specifically during outcome measure assessment. The protocols of 3 studies (Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) were registered in the Clinical Trial Registry. In other bias, all eight studies were supported by nonprofit institutions and accounted for baseline comparability, but no study provided sample size estimation information.

**Animal Studies**

The quality scores of studies included varied from 4 to 7 out of 10 points with the average of 5.73. Of which, 4 studies (Feng et al., 2009b; Wang et al., 2015; Liu, 2016; Yao, 2016) got 4 points; 6 studies (Li et al., 2009; Xu et al., 2010; Chen and Li, 2011; Xu et al., 2011; Liu et al., 2015; Shi et al., 2016) got 5 points; 13 studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Choi et al., 2011; Gao et al., 2011; Song et al., 2013; Wang et al., 2014; Zhao et al., 2014; Zheng et al., 2017) got 6 points; and 6 studies (Hwang et al., 2014; Qi et al., 2014; Oh et al., 2015; Bao et al., 2016; Ma et al., 2017; Delgado et al., 2019) got 7 points. All the included records described appropriate animal models (aged or female involved) and used an anesthetic without significant intrinsic neuroprotective activity. However, no study reported blinded induction of model, blinding their assessment of outcome, and a sample size calculation. Twenty-nine studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Choi et al., 2011; Gao et al., 2011; Song et al., 2013; Wang et al., 2014; Zhao et al., 2014; Zheng et al., 2017) were peer-reviewed publications. Twenty-seven studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Choi et al., 2011; Gao et al., 2011; Xu et al., 2011; Song et al., 2013; Hwang et al., 2014; Qi et al., 2014; Wang et al., 2014; Zhao et al., 2014; Liu et al., 2015; Oh et al., 2015; Wang et al., 2015; Bao et al., 2016; Shi et al., 2016; Yao, 2016; Ma et al., 2017; Zheng et al., 2017; Delgado et al., 2019) were peer-reviewed publications. Twenty-seven studies (Feng et al., 2009a; Feng et al., 2009b; Feng et al., 2009c; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Gao et al., 2011; Xu et al., 2011; Song et al., 2013; Hwang et al., 2014; Qi et al., 2014; Zhao et al., 2014; Liu et al., 2015; Oh et al., 2015; Wang et al., 2015; Bao et al., 2016; Liu, 2016; Shi et al., 2016; Yao, 2016; Ma et al., 2017; Delgado et al., 2019) were peer-reviewed publications. Twenty-four studies (Feng et al., 2009a; Feng et al., 2009b; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Gao et al., 2011; Xu et al., 2011; Song et al., 2013; Hwang et al., 2014; Qi et al., 2014; Zhao et al., 2014; Liu et al., 2015; Oh et al., 2015; Wang et al., 2015; Bao et al., 2016; Liu, 2016; Shi et al., 2016; Yao, 2016; Ma et al., 2017; Delgado et al., 2019) were peer-reviewed publications.

**TABLE 2 | Statement of the characteristic of Panax ginseng C. A. Mey and its compounds(a).**

| First Authors; year | Drugs; | Approach to achieving | Chemical analysis | Composition |
|---------------------|--------|-----------------------|------------------|-------------|
| Engels et al., 1996 | G115   | Pharmaten Ltd., Lugano, Switzerland | included-HPLC | Contain 4% ginsenosides(Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Re 0.714%, Rb2 0.567%, Rd 0.268%) HPLC data from F. Soldati and Sticher, 1980. |
| Engels et al., 2001 | G115   | Pharmaten Ltd., Lugano, Switzerland | included-HPLC | Contain 4% ginsenosides(Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Re 0.714%, Rb2 0.567%, Rd 0.268%) HPLC data from F. Soldati and Sticher, 1980. |
| Engels et al., 2003 | G115   | Pharmaten Ltd., Lugano, Switzerland | included-HPLC | Contain 4% ginsenosides(Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Re 0.714%, Rb2 0.567%, Rd 0.268%) HPLC data from F. Soldati and Sticher, 1980. |
| Hartz et al., 2004 | extract of PG | Frontier Herbs of Norway, IA, Norway | included-HPLC | Contain 0.112%eleutheroside B and eleutheroside E |
| Kim et al., 2016 | URSA Complex (contain dried PG extract); | not reported | included-HPLC | Contain dried ginseng extracts 50 mg |
| Hyeong-Geug et al., 2013 | bespoke 20% ethanol extract of PG; | Guryoung Pharmaceutical Company Ltd., Cheorwon, South Korea | included-HPLC | Contain 2% ginsenosides(Rb3 0.633%, Rb1 0.514%, Rb2 0.36%, Rc 0.261%, Rg3 0.108%, Rd 0.043%, Rh2 0.0002%) HPLC data from Hyeong-Geug et al., 2013. |
| Lee et al., 2016 | Enzyme-modified ginseng extract (EMGE); | not reported | included-HPLC | Rg1, Rb1, Rb3(S), Rg3(R), Compound K, Rh2(S), Rh2(R);(similar to G115 by HPLC) HPLC data from Lee et al., 2016. |
| Gal et al., 1996 | PMR Paxton Capsule (contain G115); | Pharmaten Ltd., Lugano, Switzerland | included-HPLC | Contain 4% ginsenosides(Rgl 0.548%, Re 0.352%, Rf 0.270%, Rg2 0.065%, Rbl 1.338%, Re 0.714%, Rb2 0.567%, Rd 0.268%) HPLC data from F. Soldati and Sticher, 1980. |

G115, standardized P. ginseng C.A. Mey concentrate; HPLC: high-performance liquid chromatography; PG, Panax ginseng C. A. Mey.
TABLE 3 | Characteristics of the included animal studies.

| Study (years) | Species | Sex | Weight | Mice | Anesthetic | Model (method) | Experimental group (drugs, concentration, administration, duration) | Control group | Outcome measure | Intergroup differences* |
|---------------|---------|-----|--------|------|------------|----------------|---------------------------------------------------------------------|---------------|-----------------|------------------------|
| Xu et al., 2011 | KM mice | NG  | 18–22 g | 240  | –          | weight-loaded swimming (WLS) test | ginseng protein (0.1, 0.2, 0.4 g/kg) ig, 30 days | Distilled water for same volume | 1. Mice body weight | 1. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 2. Swimming time in mice | 2. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 3. BLA | 3. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 4. Liver glycogen | 4. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 5. Serum urea nitrogen | 5. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 1. Mice body weight | 1. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 2. Swimming time in mice | 2. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 3. BLA | 3. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 4. Liver glycogen | 4. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 5. Serum urea nitrogen | 5. P>0.05 |
| Wang et al., 2010 | ICR mice | M   | (11–12 weeks) | 104 | –          | Forced swimming test | WGP (50,100,200 mg/kg) WGPA(40,100,160,200 mg/kg) WGPN(40,100,160,200 mg/kg) ig, 15 days | NS for same volume | 1. Serum GLU | 1. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 2. Serum TG | 2. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 3. Serum CK | 3. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 4. Serum LDH | 4. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 5. Serum MDA | 5. P<0.001 |
|               |         |     |        |      |            |                |                                                                 | 6. Serum SOD | 6. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 7. Serum GSH-Px | 7. P<0.05 |
| Wang et al., 2013 | ICR mice | M   | (11–12 weeks) | 104 | –          | Forced swimming test | WGP (200 mg/kg) WGPA-A(200 mg/kg) WGPA-N(200 mg/kg) ig, 15 days | NS for same volume | 1. Mice body weight | 1. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 2. Swimming time in mice | 2. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 3. Serum GLU | 3. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 4. Serum LDH | 4. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 5. Serum MDA | 5. P<0.001 |
| Song et al., 2013 | Wistar rat | M   | 180–220 g | 60   | –          | Forced swimming test | PTS (25, 50, 100 mg/kg) ig, 7 weeks | NS for same volume | 1. Mice body weight | 1. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 2. Swimming time in mice | 2. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 3. Serum GLU | 3. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 4. Serum MDA | 4. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 5. Blood lactic acid | 5. P<0.05 |
| Xu et al., 2010 | SD rat  | M   | 180–200 g | 30   | –          | Horizontal treadmill exercise | Ginsenoside Rb1(50 mg/kg) ig, 14 days | NS for same volume | 1. Skeletal muscle MDA | 1. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 2. Skeletal muscle SOD | 2. P<0.05 |
| Feng et al., 2010a | SD rat  | M   | 180–220 g | 40   | –          | Horizontal treadmill exercise | Ginsenoside (50 mg/kg) Ginsenoside Rb1(50 mg/kg) ig, 14 days | NS for same volume | 1. Calcium content in skeletal muscle cell | 1. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 2. Mitochondrial membrane potential | 2. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 3. Skeletal muscle MDA | 3. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 4. Skeletal muscle SOD | 4. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 5. Skeletal muscle GLU | 5. P<0.05 |
| Feng et al., 2009a | SD rat  | M   | 180–220 g | 40   | –          | Horizontal treadmill exercise | Ginsenoside (50 mg/kg) Ginsenoside Re (50 mg/kg) ig, 14 days | NS for same volume | 1. Hypothalamus Ach | 1. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 2. Hypothalamus DA | 2. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 3. Hypothalamus 5-HT | 3. P<0.05 |
|               |         |     |        |      |            |                |                                                                 | 4. Hypothalamus GABA | 4. P<0.01 |
| Liu, 2016      | SD rat  | M   | 240 ± 20 g | 40   | –          | Horizontal treadmill exercise | Ginsenoside Rg1(30 mg/kg) ig, 8 weeks | NS for same volume | 1. Mice body weight | 1. P>0.05 |
|               |         |     |        |      |            |                |                                                                 | 2. Exhaustion time | 2. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 3. Skeletal muscle SOD | 3. P<0.01 |
|               |         |     |        |      |            |                |                                                                 | 4. Skeletal muscle GSH-Px | 4. P<0.05 |

(Continued)
| Study (years) | Species | Sex | Weight | Anesthetic | Model (method) | Experimental group (drugs, concentration, administration, duration) | Control group | Outcome measure | Intergroup differences* |
|--------------|---------|-----|--------|------------|----------------|-----------------------------------------------------------------|---------------|----------------|---------------------|
| Feng et al., 2010b | SD rat | M | 180–220 g | – | Horizontal treadmill exercise | Ginsenoside Rb1 (50 mg/kg) | NS for same volume | 1. Hypothalamus Ach <0.01 |
|               |         |    | 40     |           |                | Ginsenoside Rg1 (50 mg/kg) ig, 14 days |               | 2. Hypothalamus DA <0.01 |
|               | Wang et al., 2015 | KM mice | M | 20 ± 2 g | – | weight-loaded swimming (WLS) test | Ginsenoside Rg1 (5, 10, 20, 40, 80 mg/kg) ig, 2 weeks | NS for same volume | 1. Swimming time <0.05 |
|               |         |    | 180    |           |                |                                                                      |               | 2. Blood lactic acid <0.05 |
|               | Yao, 2016 | mice | M | 19–22 g | – | weight-loaded swimming (WLS) test | Ginsenoside (0.8, 1.6, 3.2 g/kg) ig, 28 days | distilled water for same volume | 1. Serum BUN <0.05 |
|               | Liu et al., 2015 | mice | M | 18–22 g | – | weight-loaded swimming (WLS) test | Ginsenoside (0.8, 1.6, 3.2 g/kg) ig, 28 days | distilled water for same volume | 1. Serum BUN <0.05 |

(Continued)
| Study (years) | Species | Sex | Weight | Anesthetic | Model (method) | Experimental group (drugs, concentration, administration, duration) | Control group | Outcome measure | Intergroup differences* |
|--------------|---------|-----|--------|------------|---------------|----------------------------------------------------------|--------------|----------------|---------------------|
| Feng et al., 2009b | SD rat M | 180–220 g 30 | – | Horizontal treadmill exercise | Ginsenoside Re (50 mg/kg) ig, 14 days | NS for same volume | 1. Serum MDA | 1. P<0.01 | 2. Liver MDA | 2. P<0.01 |
| | | | | | | | 3. Skeletal muscle MDA | 3. P<0.01 | 4. Serum SOD | 4. P<0.01 |
| | | | | | | | 5. Liver SOD | 5. P<0.01 | 6. Skeletal muscle SOD | 6. P<0.01 |
| Feng et al., 2010c | SD rat M | 180–220 g 30 | – | Horizontal treadmill exercise | Ginsenoside Rg1 (50 mg/kg) ig, 14 days | NS for same volume | 1. Calcium content in skeletal muscle | 1. P<0.01 | 2. Mitochondrial membrane potential | 2. P<0.01 |
| | | | | | | | 3. Skeletal muscle SOD | 3. P<0.01 | 4. Skeletal muscle MDA | 4. P<0.01 |
| Pan et al., 2010a | SD rat M | 180–220 g 30 | – | Horizontal treadmill exercise | Ginsenosides (50 mg/kg) ig, 14 days | NS for same volume | 1. Calcium content in skeletal muscle | 1. P<0.01 | 2. Mitochondrial membrane potential | 2. P<0.01 |
| | | | | | | | 3. Skeletal muscle SOD | 3. P<0.01 | 4. Skeletal muscle MDA | 4. P<0.01 |
| Chen and Li, 2011 | SD rat M | 160–200 g 45 | Celiac anesthesia with chloral hydrate | Horizontal treadmill exercise | Ginsenosides (70 mg/kg) ig, 8 weeks | NS for same volume | 1. Hippocampus tissue GABA | 1. P<0.05 | 2. Hippocampus tissue Ach | 2. P<0.05 |
| | | | | | | | 3. Hippocampus tissue NE | 3. P<0.05 | 4. Hippocampus tissue DA | 4. P<0.05 |
| | | | | | | | 5. Hippocampus tissue 5-HT | 5. P<0.05 | 6. DA/5-HT | 6. P<0.05 |
| Pan et al., 2009 | SD rat M | 180–220 g 40 | – | Horizontal treadmill exercise | Ginsenosides (50 mg/kg) Ig | NS for same volume | 1. Hippocampus tissue GABA | 1. P<0.01 | 2. Hippocampus tissue DA | 2. P<0.01 |
| | | | | | | | 3. Hippocampus tissue 5-HT | 3. P<0.01 | 4. Hippocampus tissue Ach | 4. P<0.05 |
| Li et al., 2009 | KM mice M | 18–22 g 80 | – | weight-loaded swimming (WLS) test | Pseudo-ginsenoside GQ/PQ (0.2, 0.4, 0.8 g/kg) ig, 5 weeks | NS for same volume | 1. Mouse body weight | 1. P<0.05 | 2. Swimming time in mice | 2. P<0.01 |
| | | | | | | | 3. Blood lactic acid | 3. P<0.05 | 4. Serum BUN | 4. P<0.05 |
| | | | | | | | 5. Serum LDH | 5. P<0.05 | 6. Muscle glycogen | 6. P<0.05 |

(Continued)
| Study (years) | Species Sex Weight | Anesthetic | Model (method) | Experimental group (drugs, concentration, administration, duration) | Control group | Outcome measure | Intergroup differences* |
|----------------|---------------------|-------------|----------------|---------------------------------------------------------------|---------------|-----------------|-------------------------|
| Feng et al., 2009c | SD rat M 180–220 g 40 | – | Horizontal treadmill exercise | Ginsenoside Rb1(50 mg/kg) Ginsenoside Re(50 mg/kg) ig, 14 days | NS for same volume | 1. Hippocampus tissue DA 2. Hippocampus tissue 5-HT 3. Hippocampus tissue GABA 4. Hippocampus tissue Ach | |
| Pan et al., 2010b | SD rat M 180–220 g 30 | – | Horizontal treadmill exercise | Ginsenoside Rb1 (50 mg/kg) ig, 14 days | NS for same volume | 1. Serum MDA 2. Serum SOD 3. Liver MDA 4. Liver SOD | |
| Bao et al., 2016 | ICR mice M 18–22 g 240 | – | Forced Swimming Test | GOP (125, 250, 500 mg/kg) ig, 30 days | Distilled water for same volume | 1. Mice body weight 2. Swimming time in mice 3. Serum LDH 4. Serum Urea Nitrogen 5. Hepatic Glycogen 6. Blood Lactic Acid 7. skeletal muscle SOD 8. skeletal muscles CAT 9. skeletal muscles MDA 10. NRF-1 11. TFAM 12. mtDNA | 1. P<0.01 2. P<0.01 3. P<0.01 4. P<0.01 5. P<0.01 6. P<0.01 7. P<0.01 8. P<0.01 9. P<0.01 10. P<0.05 11. P<0.05 12. P<0.05 |
| Oh et al., 2015 | ICR mice M 26–28 g 49 | – | weight-loaded swimming (WLS) test and Rota-rod test | PPD (5, 10 mg/kg) PPT (5, 10 mg/kg) ig, 5 days | Distilled water for same volume | 1. Swimming time 2. Serum corticosterone 3. Serum GLU 4. Serum lactate 5. Serum LDH 6. Serum FFA 7. Serum creatinine 8. Serum corticosterone 9. Serum lactate 10. Serum FFA 11. Serum creatinine | 1. P<0.05 or P<0.01 2. P<0.05 or P<0.01 3. P<0.05 or P<0.01 4. P<0.05 or P<0.01 5. P<0.05 or P<0.01 6. P<0.05 or P<0.01 7. P<0.05 or P<0.01 8. P<0.01 9. P<0.05 | (Continued)
| Study (years) | Species Sex Weight N | Anesthetic | Model (method) | Experimental group (drugs, concentration, administration, duration) | Control group | Outcome measure | Intergroup differences* |
|---------------|----------------------|------------|----------------|-------------------------------------------------|---------------|----------------|------------------------|
| Qi et al., 2014 | KM mice  F/M 20 ± 2 g 80 | – | Forced swimming test | AGP (125, 250, 500 mg/kg) ig, 28 days | Distilled water for same volume | 1. Swimming time | 10. P<0.05 11. P<0.05 |
| | | | | | | 2. BLA | |
| | | | | | 3. SUN | |
| | | | | | 4. hepatic glycogen | |
| | | | | | 5. Serum GSH-Px | |
| | | | | | 6. Serum SOD | |
| | | | | | 7. Serum MDA | |
| | | | | | 1. P<0.01 | |
| | | | | | 2. P<0.01 | 3. P<0.01 |
| | | | | | 4. P<0.01 | 5. P<0.01 |
| | | | | | 6. P<0.01 | 7. P<0.01 |
| Li et al., 2018 | ICR mice  M 18-22 g 240 | – | Forced swimming test | QOPs (225, 450, 900 mg/kg) ig, 30 days | NS for same volume | 1. Swimming time | |
| | | | | | 2. Serum LDH | 1. P<0.01 |
| | | | | | 3. BUN | 2. P<0.01 |
| | | | | | 4. Hepatic glycogen | 3. P<0.01 |
| | | | | | 5. BLA | 4. P<0.01 |
| | | | | | 6. skeletal muscle SOD | 5. P<0.01 |
| | | | | | 7. skeletal muscles GSH-Px | 6. P<0.01 |
| | | | | | 8. skeletal muscles MDA | |
| | | | | | 9. Na+-K+-ATPase | 10. P<0.01 |
| | | | | | 10. Ca2+-Mg2+-ATPase | 11. P<0.01 |
| | | | | | 11. SDH | 12. P<0.01 |
| Zhao et al., 2014 | KM mice  F/M 18-22 g 70 | – | weight-loaded swimming (WLS) test | Ginseng (0.2 ml/10 g) Red Ginseng (0.2 ml/10 g) mild property ginseng (0.2 ml/10 g) ig, 14 days | Distilled water for same volume | 1. Swimming time | 11. P<0.01 |
| | | | | | 2. hypoxia tolerance time | 12. P<0.01 |
| | | | | | 3. BLA | 13. P<0.01 |
| | | | | | 4. Hepatic glycogen | 14. P<0.01 |
| | | | | | 5. muscle glycogen | |
| | | | | | 3. P>0.05 | 6. P<0.01 |
| | | | | | 4. P>0.05 | 7. P<0.01 |
| | | | | | 5. P<0.01 | 8. P<0.01 |
| | | | | | 6. P<0.01 | 9. P<0.01 |
| Gao et al., 2011 | mice  M 18-22 g 120 | – | weight-loaded swimming (WLS) test | Ginseng (1.25, 2.5, 5 mg/kg) Red Ginseng (1.25, 2.5, 5 mg/kg) | NS for same volume | 1. Swimming time | |
| | | | | | 2. Serum SOD | 1. P<0.05 |
| | | | | | 3. Serum LDH | 2. P<0.05 |
| | | | | | 4. Serum SOD | 3. P<0.05 |
| | | | | | 5. Hepatic glycogen | 4. P<0.05 |
| | | | | | 6. muscle glycogen | 5. P<0.01 |
| | | | | | 6. P<0.01 | 7. P<0.01 |
| Ma et al., 2017 | ICR mice  M NG 24 | – | Forelimb Grip Strength/weight-loaded swimming (WLS) test | CMG extract (5, 25 mg/kg) ig, 4 weeks | Distilled water for same volume | 1. Forelimb grip strength | 4. P<0.01 |
| | | | | | 2. Swimming time | 5. P<0.01 |
| | | | | | 3. Serum Lactate | 6. P<0.01 |
| | | | | | 4. Serum NH3 | 7. P<0.01 |

(Continued)
| Study (years) | Species | Sex | Weight | Model (method) | Experimental group (drugs, concentration, administration, duration) | Control group | Outcome measure | Intergroup differences* |
|--------------|---------|-----|--------|----------------|---------------------------------------------------------------|--------------|----------------|--------------------|
| Choi et al., 2011 | ICR mice | M | 17–20 g | – | restraint stress/Overcoming electroshock/Cold swimming test/Rota-rod test | RG (50, 100, 200, 400 mg/kg) ig, 7 days | NR | 1. Serum CORT 2. Blood lactic acid |
| Hwang et al., 2014 | ICR mice | M | 43 | – | aerobic running exercise | RG(1 g/kg) ig, 2 weeks | Distilled water for same volume | 1. body weight 2. Carbohydrate Oxidation 3. Fat Oxidation 4. Serum Free fatty acid |
| Shi et al., 2016 | KM mice | M | 18–22 g | – | weight-loaded swimming (WLS) test and Rota-rod test | BG(1.65, 3.30, 4.95 g/kg) ig, 2 weeks | Distilled water for same volume | 1. body weight 2. pole-climbing time 3. swimming time |

5-HT, 5-hydroxytryptamine; Ach, acetylcholine; BLA, Blood lactic acid; BUN, blood urea nitrogen; CK, creatine phosphokinase; CORT, corticosterone; DA, dopamine; GABA, gamma-aminobutyric acid; GLU, glucose; GSH-Px, glutathione peroxidase; LDH, lactic dehydrogenase; MDA, malondialdehyde; mtDNA, mitochondrial DNA; NRF-1, Nuclear respiratory factor 1; PTS, panaxtrol saponin; SDH, succinate dehydrogenase; SOD, superoxide dismutase; TG, triglyceride; TFAM, Mitochondrial transcription factor A; WGP, water-soluble ginseng polysaccharides; WGPA, ginseng pectin; WGPN, starch-like glucans.
| Study            | Herb source          | Type of herbal or bioactive compound | Purity | Approach to achieving | Quality control (lot number) | Chemical analysis | Structure or Composition |
|-----------------|----------------------|-------------------------------------|--------|-----------------------|-----------------------------|-------------------|--------------------------|
| Xu et al., 2011 | Panax ginseng C.A. Mey | Ginseng proteins                     | 80%    | not reported          | Not reported                | Included-UC       | –                        |
| Wang et al., 2010 | Panax ginseng C.A. Mey | Ginseng polysaccharides              | not reported | the School of Life Sciences, Northeast Normal University, China | reported (20081001) | Included-HPLC | –                        |
| Wang et al., 2013 | Panax ginseng C.A. Mey | Ginseng pectin polysaccharide        | not reported | the School of Life Sciences, Northeast Normal University, China | reported (20081001) | Included-HPLC | –                        |
| Song et al., 2013 | Panax ginseng C.A. Mey | PTS                                  | not reported | the School of Life Sciences, Northeast Normal University, China | not reported | not included | –                        |
| Xu et al., 2010  | Panax ginseng C.A. Mey | Ginsenoside Rb1                      | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | Included-HPLC | –                        |
| Feng et al., 2010a | Panax ginseng C.A. Mey | Ginsenoside Rb1                      | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | Included-HPLC | –                        |
| Feng et al., 2010a | Panax ginseng C.A. Mey | Ginsenoside Re                       | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | Included-HPLC | –                        |

(Continued)
| Study          | Herb source       | Type of herbal or bioactive compound | Purity       | Approach to achieving | Quality control (lot number) | Chemical analysis | Structure or Composition |
|---------------|-------------------|--------------------------------------|--------------|------------------------|------------------------------|-------------------|--------------------------|
| Liu, 2016     | Panax ginseng C.A. Mey | Ginsenoside Rg1                      | 98.59%       | Dingguo Biotechnology Co., Ltd., China | not reported                | included-HPLC        | ![Structure](image1)      |
| Feng et al., 2010b | Panax ginseng C.A. Mey | Ginsenoside Rb1, Ginsenoside Rg1      | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | included-HPLC | ![Structure](image2)      |
| Wang et al., 2015 | Panax ginseng C.A. Mey | Ginsenoside Rg1                      | 98%          | Department of Organic Chemistry, Basic Medical College of Jilin University, Jilin, China | not reported | included-HPLC | ![Structure](image3)      |
| Yao, 2016     | Panax ginseng C.A. Mey | Ginsenoside                        | not reported | not reported | not reported                | not included        | ![Structure](image4)      |
| Liu et al., 2015 | Panax ginseng C.A. Mey | Ginsenoside                        | > 80%        | Xi'an Ruiying Biotechnology Co., Ltd., Xi'an, China | reported (RYR20140325) | not included  | ![Structure](image5)      |
| Feng et al., 2009b | Panax ginseng C.A. Mey | Ginsenoside Re                       | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | Reported according to (07120623) | included-HPLC | ![Structure](image6)      |
| Study          | Herb source        | Type of herbal or bioactive compound | Purity | Approach to achieving quality control | Quality control (lot number) | Chemical analysis | Structure or Composition |
|---------------|--------------------|--------------------------------------|--------|---------------------------------------|------------------------------|-------------------|------------------------|
| Feng et al., 2010c | Panax ginseng C.A. Mey | Ginsenoside Rg1 | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | reported | included-HPLC | ![Diagram](image1) |
| Pan et al., 2010a | Panax ginseng C.A. Mey | Ginsenosides | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | included-HPLC | ![Diagram](image2) |
| Chen and Li, 2011 | Panax ginseng C.A. Mey | Ginsenosides | not reported | Jilin Yawei Pharmaceutical Co., Ltd., Jilin, China | Reported | included-HPLC | ![Diagram](image3) |
| Pan et al., 2009 | Panax ginseng C.A. Mey | Ginsenosides | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | included-HPLC | ![Diagram](image4) |
| Li et al., 2009 | Panax ginseng C.A. Mey | Pseudo-ginsenoside GQ Rg | 98.7% | Institute of Regenerative Medicine, Jilin University, Jilin, China | not reported | not included | ![Diagram](image5) |
| Feng et al., 2010c | Panax ginseng C.A. Mey | Ginsenoside Rb1 | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | included-HPLC | ![Diagram](image6) |
| Pan et al., 2010b | Panax ginseng C.A. Mey | Ginsenoside Rb1 | not reported | Shanghai Tongtian Biotechnology Co., Ltd., Shanghai, China | not reported | included-HPLC | ![Diagram](image7) |
| Bao et al., 2016 | Panax ginseng C.A. Mey | Ginseng oligopeptides (GOP) | 95.42% | Jilin Taigu Biological Engineering Co., Ltd., Jilin, China | not reported | included-HPLC | ![Diagram](image8) |

(Continued)
###TABLE 4 | Continued

| Study | Herb source | Type of herbal or bioactive compound | Purity | Approach to achieving Quality control (lot number) | Chemical analysis | Structure or Composition |
|-------|-------------|-------------------------------------|--------|-----------------------------------------------|------------------|---------------------------|
| Oh et al., 2015 | Panax ginseng C.A. Mey | 20(S)-Protopanaxadiol (PPD) 20(S)-Protopanaxatriol (PPT) | ≥98% | the College of Pharmacy, Kyung Hee University, Geumsan, Korea | included-HPLC | – |
| Qi et al., 2014 | Panax quinquefolium | American ginseng proteins (AGP) small-molecule oligopeptides isolated from American ginseng (QOPs) | 80% | Agilent Technologies, USA | not reported | included-HPLC |
| Li et al., 2018 | Panax quinquefolium | Red Ginseng mild property ginseng | 96.46% | SinoMed Peptide Valley Biotechnology Co., Ltd., China | reported (CN105154509A) | included-HPLC |
| Zhao et al., 2014 | Red ginseng | Ginseng Red Ginseng | not reported | not reported | not included | Red Ginseng Contain 4.015% ginsenosides (Rg1 0.262%, Re 0.145%, Rf 0.151%, Rh1 0.284%, Rg2 0.402%, Rb1 0.394%, Rb2 0.247%, Rb3 0.465%, Rd 0.437%, Rg3 0.412%, Rk1 0.194%, Rg5 0.304%) HPLC data from Kim et al., 2007 |
| Gao et al., 2011 | Panax ginseng C.A. Mey | Ginseng Red Ginseng | not reported | not reported | not included | Red Ginseng Contain 4.015% ginsenosides (Rg1 0.262%, Re 0.145%, Rf 0.151%, Rh1 0.284%, Rg2 0.402%, Rb1 0.394%, Rb2 0.247%, Rb3 0.465%, Rd 0.437%, Rg3 0.412%, Rk1 0.194%, Rg5 0.304%) HPLC data from Kim et al., 2007 |
| Ma et al., 2017 | Panax ginseng C.A. Mey | Changbai Mountain Ginseng(CMG) | not reported | not reported | not included | Contain 11.5% ginsenosides (R1 0.46%, R2 0.69%, Rb1 0.22%, Rb2 0.94%, Rb3 1.22%, Rb 0.33%, Rd 1.54%, Re 0.11%, Rf 1.14%, Rg1 0.22%, Rg2 0.64%, 20-glc-G-Rf 1.60%, R1 0.71%, R2 1.15%) HPLC data from Wang et al. 2017 |
| Choi et al., 2011 | Red ginseng | Ren Ginseng | not reported | not reported | not included | Contain 4.015% ginsenosides (Rg1 0.262%, Re 0.145%, Rf 0.151%, Rh1 0.284%, Rg2 0.402%, Rb1 0.394%, Rb2 0.247%, Rb3 0.465%, Rd 0.437%, Rg3 0.412%, Rk1 0.194%, Rg5 0.304%) HPLC data from Kim et al., 2007 |
| Hwang et al., 2014 | Red ginseng | Ren Ginseng | not reported | not reported | not included | Contain 1.964% ginsenosides (Rg1 0.071%, Re 0.050%, Rf 0.121%, R1 0.078%, Rg2a 0.192%, Rg2 0.129%, Rb1 0.462%, Rb2 0.183%, Rd 0.089%, Rg3 0.214%, Rg4 0.091%) HPLC data from Hwang et al., 2014 |
| Shi et al., 2016 | Black ginseng | black Ginseng | not reported | not reported | not included | Contain 3.341% ginsenosides (Rg1 0.232%, Re 0.188%, Rf 0.158%, Rb1 0.184%, Rb2 0.174%, Rd 0.169%, Rb6 0.138%, F4 0.127%, Rf 0.162%, Rg1 0.102%, 20(S)-Rg3 0.173%, 20(R)-Rg3 0.121%, 20(S)-Rg2 0.114%, 20(S)-Rs3 0.215%, Rb1 0.178%, Rg5 0.321%, Rd 0.225%, Rg6 0.197%) HPLC data from Sun et al., 2009 |

HPLC, high-performance liquid chromatography; PGC, ginseng and its compounds.
et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Chen and Li, 2011; Gao et al., 2011; Choi et al., 2011; Song et al., 2013; Hwang et al., 2014; Qi et al., 2014; Wang et al., 2014; Zhao et al., 2014; Oh et al., 2015; Bao et al., 2016; Liu, 2016; Shi et al., 2016; Ma et al., 2017; Zheng et al., 2017; Delgado et al., 2019) described control of temperature. Twenty-four studies (Feng et al., 2009a; Feng et al., 2009b; Li et al., 2009; Pan et al., 2009; Feng et al., 2010a; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Choi et al., 2011; Gao et al., 2011; Xu et al., 2011; Song et al., 2013; Hwang et al., 2014; Qi et al., 2014; Wang et al., 2014; Zhao et al., 2014; Zhao et al., 2014; Liu et al., 2015; Oh et al., 2015; Bao et al., 2016; Liu, 2016; Ma et al., 2017; Zheng et al., 2017; Delgado et al., 2019) declared no potential conflict of interests, and 9 studies (Choi et al., 2011; Huang et al., 2014; Qi et al., 2014; Wang et al., 2014; Oh et al., 2015; Bao et al., 2016; Ma et al., 2017; Zheng et al., 2017; Delgado et al., 2019) reported compliance with animal welfare regulations. The methodological quality is concluded in Table 6.

Effectiveness
Randomized Control Trials
Five studies (Gal et al., 1996; Hartz et al., 2004; Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) described the treatment of CFS patients. These studies utilized different scales of fatigue to measure therapeutic effect. Therefore, the meta-analysis was not conducted because of different evaluation criteria. All studies showed significant difference in their respective fatigue scales for PGC relative to placebo. Three studies (Gal et al., 1996; Hartz et al., 2004; Kim et al., 2016) reported clinical effect, which according to different self-reported fatigue scales. Meta-analysis of 3 studies (Gal et al., 1996; Hartz et al., 2004; Kim et al., 2016) found significant difference in clinical effect for PGC relative to placebo (nT/nC = 181/133, OR = 1.31, 95% CI: 1.17 to 1.46, P < 0.00001; heterogeneity: $\chi^2 = 1.94$, df = 2 (P = 0.38), I$^2$ = 0%) (Figure 2A). Meta-analysis of 5 studies (Gal et al., 1996; Hartz et al., 2004; Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) showed there was no significant difference in the frequency of adverse events between the groups (nT/nC = 293/297, OR = 1.09, 95% CI: 0.48 to 2.46, P = 0.83, heterogeneity: $\chi^2 = 6.99$, df = 4 (P = 0.14), I$^2$ = 0%) (Figure 2B).

Three studies (Engels et al., 1996; Engels et al., 2001; Engels et al., 2003) described the effect of PGC on physical performance recovery of healthy adults after exercise fatigue. Meta-analysis of 3 studies (Engels et al., 1996; Engels et al., 2001; Engels et al., 2003) found significant difference in heart rate recovery after exercise compared the PGC with placebo (nT/nC = 35/30; FE = $−5.73$, 95% CI, $−9.22$ to $−2.55$; $P = 0.001$; heterogeneity: $\chi^2 = 3.80$, df = 2 ($P = 0.15$), I$^2$ = 47%) (Figure 2C).

Animal Studies
The Swimming Time
Meta-analysis of 8 studies (Li et al., 2009; Xu et al., 2011; Zhao et al., 2014; Liu et al., 2015; Wang et al., 2015; Shi et al., 2016; Yao, 2016; Ma et al., 2017) showed PGC significantly increased the swimming time in WLST compared with control (n = 98, SMD = $2.21$, 95% CI: $1.83$ to $2.59$, $P < 0.00001$; heterogeneity: $\chi^2 = 18.96$, df = 7 ($P = 0.008$), I$^2$ = 63%). Owing to obvious heterogeneity, we used sensitivity analyses and removed one study (Li et al., 2009) that trained the mice before the swimming test. Meta-analysis of 7 studies showed a significant effect of PGC in increasing the swimming time in WLST compared with control (n = 78, SMD = $2.60$, 95% CI: $2.14$ to $3.06$, $P < 0.00001$; heterogeneity: $\chi^2 = 9.75$, df = 6 ($P = 0.14$), I$^2$ = 38%) (Figure 3A). Five studies (Choi et al., 2011; Song et al., 2013; Qi et al., 2014; Song et al., 2013; Shi et al., 2016) showed there was no significant difference in heart rate recovery after exercise compared the PGC with placebo (nT/nC = 35/30; FE = $−5.73$, 95% CI, $−9.22$ to $−2.55$; $P = 0.001$; heterogeneity: $\chi^2 = 3.80$, df = 2 ($P = 0.15$), I$^2$ = 47%) (Figure 2C).
FIGURE 2 | (A) Clinical effect of Panax ginseng C. A. Mey and its compounds versus Placebo. (B) Adverse events of Panax ginseng C. A. Mey and its compounds versus Placebo. (C) Heart rate recovery of Panax ginseng C. A. Mey and its compounds versus Placebo.

FIGURE 3 | (A) Forced swimming test of Panax ginseng C. A. Mey and its compounds versus Control. (B) Weight-loaded swimming test of Panax ginseng C. A. Mey and its compounds versus Control.
et al., 2014; Bao et al., 2016; Delgado et al., 2019) found that PGC was more effective in increasing the swimming time in FST than that of control (n = 67, SMD = −2.78, 95% CI: −3.70 to −1.89, P < 0.00001; heterogeneity: \(\chi^2 = 4.22, df = 3 (P=0.24), I^2 = 29\%\)) (Figure 5A); five studies (Feng et al., 2009c; Pan et al., 2010a; Qi et al., 2014; Wang et al., 2014; Zheng et al., 2017) for reducing level of MDA (n = 44; SMD = −2.48; 95% CI: −3.07 to −1.89, P < 0.00001; heterogeneity: \(\chi^2 = 4.22, df = 3 (P=0.24), I^2 = 29\%\)) (Figure 5A); five studies (Feng et al., 2009c; Pan et al., 2010a; Qi et al., 2014; Wang et al., 2014; Zheng et al., 2017) for reducing level of MDA (n = 44; SMD = −2.86; 95% CI: −3.47 to −2.26, P < 0.00001; heterogeneity: \(\chi^2 = 6.42, df = 3 (P = 0.17), I^2 = 38\%\)) (Figure 5B); five studies (Feng et al., 2009c; Pan et al., 2010a; Qi et al., 2014; Wang et al., 2014; Zheng et al., 2017) for increasing level of hepatic glycogen compared with control (n = 97, SMD = 2.61, 95% CI: 2.19 to 3.03, P < 0.00001; heterogeneity: \(\chi^2 = 12.32, df = 7 (P = 0.09), I^2 = 43\%\)) (Figure 6B). Compared with control group, meta-analysis of 2 studies (Liu, 2016; Bao et al., 2016) showed that PGC had significant effect to increase activity of CAT (n = 25, SMD = 1.90, 95% CI: 1.21 to 2.59, P < 0.00001; heterogeneity: \(\chi^2 = 1.05, df = 4 (P = 0.31), I^2 = 5\%\)) (Figure 6C); 2 studies (Liu, 2016; Delgado et al., 2019) for improving activity of GSH-Px (n = 22, SMD = 2.01, 95% CI: 1.26 to 2.77, P < 0.00001; heterogeneity: \(\chi^2 = 0.47, df = 1 (P = 0.49), I^2 = 0\%\)) (Figure 6D). The level of MDA was reported in 9 studies (Feng et al., 2009c; Feng et al., 2010a; Feng et al., 2010b; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Bao et al., 2016; Liu, 2016; Delgado et al., 2019) showed that PGC was still superior to the control (n = 87, SMD = 2.96, 95% CI: 2.49 to 3.42, P < 0.00001; heterogeneity: \(\chi^2 = 23.71, df = 8 (P = 0.003), I^2 = 66\%\)). Sensitivity analyses were conducted to explore potential sources of heterogeneity. After removing 1 trial (Pan et al., 2010b) that utilized crude products of PG, meta-analysis of 8 studies (Feng et al., 2009c; Feng et al., 2010a; Feng et al., 2010b; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Bao et al., 2016; Liu, 2016; Delgado et al., 2019) showed that PGC significantly improved activity of SOD (n = 97, SMD = 2.61, 95% CI: 2.19 to 3.03, P < 0.00001; heterogeneity: \(\chi^2 = 12.32, df = 7 (P = 0.09), I^2 = 43\%\)) (Figure 6B). Compared with control group, meta-analysis of 2 studies (Liu, 2016; Bao et al., 2016) showed that PGC had significant effect to increase activity of CAT (n = 25, SMD = 1.90, 95% CI: 1.21 to 2.59, P < 0.00001; heterogeneity: \(\chi^2 = 1.05, df = 4 (P = 0.31), I^2 = 5\%\)) (Figure 6C); 2 studies (Liu, 2016; Delgado et al., 2019) for improving activity of GSH-Px (n = 22, SMD = 2.01, 95% CI: 1.26 to 2.77, P < 0.00001; heterogeneity: \(\chi^2 = 0.47, df = 1 (P = 0.49), I^2 = 0\%\)) (Figure 6D). The level of MDA was reported in 9 studies (Feng et al., 2009c; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Bao et al., 2016; Liu, 2016; Delgado et al., 2019). There was significant decreasing in the level of MDA compared PGC with control (P < 0.05). No meta-analysis was carried out because of high heterogeneity.

**Skeletal Muscle Biochemical Parameters:**

Meta-analysis of 11 studies (Gao et al., 2011; Xu et al., 2011; Zhao et al., 2014; Wang et al., 2015; Ma et al., 2017) showed a significant effect of PGC for increasing level of muscle glycogen compared with control (n = 68, SMD = 0.80, 95% CI: 0.43 to 1.17, P < 0.00001; heterogeneity: \(\chi^2 = 17.10, df = 5 (P = 0.004), I^2 = 71\%\)). After removing 1 study (Feng et al., 2010b) that utilized rats as experimental subjects, meta-analysis of 5 studies (Li et al., 2009; Gao et al., 2011; Zhao et al., 2014; Wang et al., 2015; Ma et al., 2017) showed similar results (n = 58, SMD = 0.63, 95% CI: 0.25 to 1.01, P = 0.001; heterogeneity: \(\chi^2 = 6.14, df = 4 (P = 0.19), I^2 = 35\%\)) (Figure 6A). Compared with control, meta-analysis of 9 studies (Feng et al., 2009c; Feng et al., 2010a; Feng et al., 2010b; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Bao et al., 2016; Liu, 2016; Delgado et al., 2019) showed that PGC significantly improved activity of SOD (n = 97, SMD = 2.61, 95% CI: 2.19 to 3.03, P < 0.00001; heterogeneity: \(\chi^2 = 12.32, df = 7 (P = 0.09), I^2 = 43\%\)) (Figure 6B). Compared with control group, meta-analysis of 2 studies (Liu, 2016; Bao et al., 2016) showed that PGC had significant effect to increase activity of CAT (n = 25, SMD = 1.90, 95% CI: 1.21 to 2.59, P < 0.00001; heterogeneity: \(\chi^2 = 1.05, df = 4 (P = 0.31), I^2 = 5\%\)) (Figure 6C); 2 studies (Liu, 2016; Delgado et al., 2019) for improving activity of GSH-Px (n = 22, SMD = 2.01, 95% CI: 1.26 to 2.77, P < 0.00001; heterogeneity: \(\chi^2 = 0.47, df = 1 (P = 0.49), I^2 = 0\%\)) (Figure 6D). The level of MDA was reported in 9 studies (Feng et al., 2009c; Feng et al., 2010b; Feng et al., 2010c; Pan et al., 2010a; Pan et al., 2010b; Xu et al., 2010; Bao et al., 2016; Liu, 2016; Delgado et al., 2019). There was significant decreasing in the level of MDA compared PGC with control (P < 0.05). No meta-analysis was carried out because of high heterogeneity.

**Liver Biochemical Parameters:**

Meta-analysis of 11 studies (Gao et al., 2011; Xu et al., 2011; Zhao et al., 2014; Qi et al., 2014; Liu et al., 2015; Wang et al., 2015; Shi et al., 2016; Yao, 2016; Bao et al., 2016; Ma et al., 2017; Delgado et al., 2019) showed that PGC had significant effects for increasing level of hepatic glycogen compared with control (n = 135, SMD = 2.19, 95% CI: 1.86 to 2.52, P < 0.00001; heterogeneity: \(\chi^2 = 58.77, df = 10 (P < 0.0001), I^2 = 83\%\)). Owing to obvious heterogeneity, we conducted subgroup analysis. These studies were divided into 4 subgroups according to different experiment interventions. Meta-analysis showed that there was significant difference in the level of glycogen between
FIGURE 4 | (A) Level of glutathione peroxidase in serum of Panax ginseng C. A. Mey and its compounds versus Control. (B) Level of glucose in serum of Panax ginseng C. A. Mey and its compounds versus Control. (C) Level of blood urea nitrogen in serum of Panax ginseng C. A. Mey and its compounds versus Control. (D) Level of blood lactate in serum of Panax ginseng C. A. Mey and its compounds versus Control.
PGC and control in all subgroups, including ginseng (Gao et al., 2011; Zhao et al., 2014; Shi et al., 2016; Ma et al., 2017), Ginsenosides (Liu et al., 2015; Wang et al., 2015; Yao, 2016), ginseng protein (Xu et al., 2011; Qi et al., 2014), and ginseng oligopeptides (Bao et al., 2016; Delgado et al., 2019) groups (Figure 7A). Meta-analysis of 4 studies (Feng et al., 2009c; Pan et al., 2010a; Liu et al., 2015; Yao, 2016) showed that PGC significantly decreased level of MDA compared with control (n = 50; SMD = −2.01; 95% CI, −2.50 to −1.51; P < 0.00001; heterogeneity: χ² = 1.69, df = 3 (P = 0.64), I² = 0%) (Figure 7B). Meta-analysis of two studies (Liu et al., 2015; Yao, 2016) showed no significant difference in activity of GSH-Px between PGC and control (n = 30; SMD = 1.81; 95% CI, −7.98 to 11.60, P = 0.72; heterogeneity: χ² = 0.00, df = 1 (P = 1.00), I² = 0%) (Figure 7C). Activity of SOD was reported in four studies (Feng et al., 2009c; Pan et al., 2010a; Liu et al., 2015; Yao, 2016). Two studies (Feng et al., 2009c; Pan et al., 2010a) showed significant difference (P < 0.05) for increasing activity of SOD compared PGC with control, whereas 2 studies (Liu et al., 2015; Yao, 2016) showed contradictory results (P > 0.05).

Figure 5 | (A) Level of creatine kinase in serum of Panax ginseng C. A. Mey and its compounds versus Control. (B) Level of malondialdehyde in serum of Panax ginseng C. A. Mey and its compounds versus Control. (C) Level of superoxide dismutase in serum of Panax ginseng C. A. Mey and its compounds versus Control. (D) Level of lactic dehydrogenase in serum of Panax ginseng C. A. Mey and its compounds versus Control.
Brain Tissue Biochemical Parameters

Meta-analysis of 5 studies (Feng et al., 2009a; Feng et al., 2009b; Pan et al., 2009; Feng et al., 2010a; Chen and Li, 2011) showed PGC was significant for reducing level of GABA (n = 55; SMD = -4.45; 95% CI, -5.24 to -3.66; P < 0.00001; heterogeneity: $\chi^2 = 17.97$, df = 4 (P = 0.001), I$^2$ = 78%) and level of 5-HT (n = 55; SMD = -1.19; 95% CI, -1.63 to -0.76; P < 0.00001; heterogeneity: $\chi^2 = 15.52$, df = 4 (P = 0.004), I$^2$ = 74%) compared with control. One study (Chen and Li, 2011) that utilize chloral hydrate to anesthetize rats may be considered as the probable source of the heterogeneity. After getting rid of this study, there was showing that PGC better reduce the level of GABA (n = 40; SMD = -6.12; 95% CI, -7.27 to -4.96; P < 0.00001; heterogeneity: $\chi^2 = 3.10$, df = 3 (P = 0.38), I$^2$ = 3%) (Figure 8A) and 5-HT (n = 40; SMD = -1.77; 95% CI, -2.31 to -1.23; P < 0.00001; heterogeneity: $\chi^2 = 3.62$, df = 3 (P = 0.31), I$^2$ = 17%) (Figure 8B). Meta-analysis of five studies (Feng et al., 2009a; Feng et al., 2009b; Pan et al., 2009; Feng et al., 2010a; Chen and Li, 2011) found significant difference for increasing level of Ach between PGC and control groups (n = 55; SMD = 1.86; 95% CI, 1.38 to 2.23; P < 0.00001; heterogeneity: $\chi^2 = 9.70$, df = 4 (P = 0.05), I$^2$ = 59%). After removing one study (Feng et al., 2009a), meta-analysis of four studies (Feng et al., 2009b; Pan et al., 2009; Feng et al., 2010a; Chen and Li, 2011) showed similar results (n = 45; SMD = 1.66; 95% CI, 1.16 to 2.16, P < 0.00001; heterogeneity: $\chi^2 = 3.21$, df = 3 (P = 0.36), I$^2$ = 6%) (Figure 8C). Meta-analysis of five studies (Feng et al., 2009a; Feng et al., 2009b; Pan et al., 2009; Feng et al., 2010a; Chen and Li, 2011) showed a significant increase in level of DA compared PGC with control (n = 55; SMD = 1.76; 95% CI, 1.26 to 2.22, P < 0.00001; heterogeneity: $\chi^2 = 6.85$, df = 4 (P = 0.14), I$^2$ = 42%) (Figure 8D).
Animal Body Weight:
Meta-analysis of 7 studies (Li et al., 2009; Xu et al., 2011; Song et al., 2013; Hwang et al., 2014; Bao et al., 2016; Liu, 2016; Shi et al., 2016) showed there was no significant difference in body weight between PGC and control groups (n = 96; SMD = 0.07; 95% CI: -0.21 to 0.36; P = 0.62; heterogeneity: χ² = 8.87, df = 6 (P = 0.18), I² = 32%) (Figure 9A).

Publication Bias
Funnel plots were conducted for two outcomes (Figures 9B, C). The results showed symmetrical distribution for the outcomes of BUN levels (Egger’s test t = -1.05; 95% CI, -6.93 to 2.50; P = 0.320), which did not suggest an obvious publication bias. However, there was a significant bias in the BLA levels with Egger’s test (t = -3.47; 95% CI, -5.14 to -1.19; P = 0.004). Because the number of studies in the remaining outcomes was limited (n < 10), funnel plot and Egger’s test were not appropriate.

Possible Mechanisms
PGC improved activity of GSH-Px, CAT, and SOD, scavenged free radicals and their metabolites, reduced the excessive ROS, and decreased levels of MDA, CK, and LDH. PGC decreased nitric oxide synthase (NOS), reduced toxic oxidant peroxynitrite, and prevented mitochondrial dysfunction and lipid peroxidation. PGC may enhance fat mobilization and promote gluconeogenesis, increase the delivery of glucose, and maintain blood glucose level. PGC increased the LDH activity and the hepatic glycogen levels, and retarded the accumulation of BUN and BLA. PGC improved succinate dehydrogenase (SDH), Na⁺-K⁺-ATPase, and Ca²⁺Mg²⁺-ATPase activities, enhanced mitochondrial function, and produced more adenosine triphosphate (ATP). PGC attenuated MPP⁺-induced MPTP-induced and apoptosis. PGC increased Ach and DA levels, and decreased GABA and 5-HT levels in brain tissue (Figure 10).

DISCUSSION
Summary of Evidence
This is the clinical and preclinical systematic review to evaluate the efficacy and safety of PGC for fatigue. Eight RCTs with 678...
participants and 30 studies with 2249 animals were selected. The quality of RCTs included was high, and animal studies were generally moderate. The findings of RCTs demonstrated that PGC was superior to placebo according to their respective fatigue scales, heart rate recovery, and clinical effect. There were a similar number of adverse effects between PGC and placebo group. The evidence available from animal studies showed that PGC could preserve physical function after exercise, mainly through antioxidant, regulating carbohydrate metabolism, delaying the accumulation of metabolites, promoting mitochondrial function, neuroprotection, antiapoptosis, and regulating neurotransmitter disorder in central nervous system.

Limitations

Some methodological flaws existed in the primary RCTs. First of all, 3 studies used allocation concealment (Hartz et al., 2004; Hyeong-Geug et al., 2013; Lee et al., 2016). Trials with unreported or inadequate allocation concealment could be exaggerated an average 18% beneficial effect of interventions (Higgins and Green, 2011). Second, non-blinding of outcome assessment may lead to systemic errors. In previous reviews, non-blinding of outcome assessment can lead to an overestimation of treatment effect by 27% to 68%, depending on different outcome types, i.e., binary outcome, measurement scale outcome, and time-to-event outcome. However, in RCTs, blinded outcome assessment was commonly poor reported and used. In present study, only 2 RCTs (Hartz et al., 2004; Lee et al., 2016) reported blinded outcome assessment. The observer bias can be avoided by sufficient blinding. More independent assessors can be further used to increase the feasibility of blind assessment. Clinical trial registration could help to minimize bias in selective reporting and improve the validity and value of the scientific evidence (Angelis et al., 2006). Thirdly, 3 RCTs (Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) formally registered. Clinical trial registration could help to minimize bias in selective reporting and improve the validity and value of the scientific evidence (Angelis et al., 2006). Fourthly, intention to treat (ITT) analysis is a strategy to gather data as completely as possible on all randomized patients in line with their scheduled assessments (Lewis and Machin, 1993). Four RCTs (Hermann-J et al., 2003;
FIGURE 9 | (A) Body weight of Panax ginseng C. A. Mey and its compounds versus Control. (B) Funnel plots of blood urea nitrogen. (C) Funnel plots of blood lactate.
Hyeong-Geug et al., 2013; Kim et al., 2016; Lee et al., 2016) described whether they analyzed the data based on the ITT principle. Trials with incorrect or no ITT analysis may overestimate the results (Bondemark and Abdulraheem, 2017). Finally, various scales of fatigue were used as outcome measure in different trials. The evaluation of clinical efficacy rate is based on inconsistent scales, which restrict the validity and reliability. The quality of animal studies was considered to be moderate, suggesting that the results should be carefully interpreted. Fatigue can be divided into CFS and post-exercise fatigue in clinic. In the present analysis, all fatigue models are exhaustion, which may lead to ignore chronic process.

In addition, we cannot neglect the contribution of Korea and other countries worldwide in the study of ginseng in treatment of fatigue. Due to the limitation of language, the present study was not included studies which language was not English or Chinese. We can increase international cooperation to overcome the linguistic limitation.

Implications
The evidence available from present study supported the routine use of PGC for fatigue, whereas the safety still needs more data because only five of eight studies reported. Given the gap between limitations of the primary RCTs and the quality of RCTs, we recommend that further design of the RCTs should consult the CONSORT statement (Moher et al., 2005), which offer a standard way for authors to design, conduct, analyze, and interpret, and to assess the validity of results.

Currently, there is no gold standard for measuring fatigue. Various scales were used to measure fatigue in different studies. Some scales have been calibrated, and some are homemade. Measurement of fatigue is challenging. Due to the wide range of conceptualizations of the problem and the concurrent development of questionnaires for many specific diseases, many questionnaires are used to measure fatigue. A comprehensive fatigue measurement, such as the Fatigue Severity Scale (Krupp et al., 1989), Piper Fatigue Scale (Piper et al., 1998), or FACIT-F (David et al., 2010), assesses the impact of fatigue on daily activities and its severity. In addition, short fatigue measurements such as the POMS-B fatigue subscale (Mcnairpm and Dropplemannl, 1992) and the 7-item Patient Reported Outcome Measurement Information System Cancer Fatigue Short Form (Cessna et al., 2016; Garcia et al., 2016) mainly assess severity of fatigue. The fatigue measurement precision with a comprehensive measure was greater than that with short fatigue measurement in evaluating moderate to severe fatigue, whereas the short fatigue measurement performed better in evaluating mild fatigue (Voshaar et al., 2015). Therefore, we should select the suitable fatigue measurements based on the research requirements.

Degree and scope of debilitating fatigue is a core component of health care where chronic diseases are receiving increasing attention. Current acute disease research models are not enough to solve chronic disorders affecting multiple regulatory systems and present complex constellations of symptoms. The identification of objective markers consistently associated with CFS is an important goal in relation to diagnosis and treatment, as the current case definitions are based entirely on physical signs and symptoms. Since the human body is an autonomous, fully integrated, and self-regulating system, it is not surprising that even localized muscle fatigue can present systemic biomarkers. There is a growing study devoted to understanding the biology of fatigue. Recognition of CFS biomarkers is an important part of this work. A complex construct of symptoms emerges from alterations and/or dysfunctions in the nervous, endocrine, and immune systems. Biomarkers, distributing across these systems, constituted complex biological networks. The acquisition of biomarkers required a comprehensive biological network-based analysis of fatigue biology (Klimas et al., 2012). In addition, molecular aberrations observed in many CFS blood cell studies provided an opportunity to develop diagnostic analysis of blood samples. With the development of micro/nanofabrication, direct electrical detection of cellular and molecular properties, microfluidics, and artificial intelligence techniques, a nano-electronics blood-based assay have been developed, which can potentially establish

**FIGURE 10** | Possible mechanisms of Panax ginseng C. A. Mey and its compounds anti-fatigue.
diagnostic biomarkers and drug screening platform for CFS (Esfandyarpour et al., 2019).

Preclinical research is the key to convert preclinical data into clinical data (Ramirez et al., 2017). However, there is growing concern that poor experimental design and transparent reporting lead to frequent failure of translating preclinical discoveries into new therapies for human diseases (Hackam and Redelmeier, 2006). In present study, the quality of including animal studies was moderate. We recommend that further design of the studies should consult the ARRIVE guidelines (Kilkenny et al., 2012) and use appropriate animals, random allocation, model blinded induction, and outcomes blinded assessment to improve the accuracy of the results.

PGC acted through complex, multicomponent, multitarget, and multipathway mechanisms in fatigue and might prove to be of great value in further clinical trials. The possible mechanisms of PGC for fatigue are summarized as follows: (1) Antioxidant stress: PGC passed through the injured membrane, improved the activity of GSH-Px, CAT, and SOD, scavenged hydroxyl radical, and reduced the excessive ROS, and thus preventing lipid oxidation and protecting the corpuscular membrane to reduce the release of LDH, MDA, and CK into the serum (Wang et al., 2014; Zheng et al., 2017). Another mechanism might involve the nitric oxide pathway. NOS, a pro-oxidative enzyme, increased the production of toxic oxidant peroxynitrite. PGC decreased NOS and prevented peroxynitrite-induced mitochondrial dysfunction and lipid peroxidation (Ki Sung et al., 2006); (2) Regulation of carbohydrate metabolism: PGC increased the proportion of energy supplied by fat and promoted gluconeogenesis to improve hepatic glycogen storage. PGC enhanced the delivery of glucose by increasing capillary perfusion and plasma glucose concentration and increased the permeability of the muscle membrane of glucose to increase the muscle glucose uptake during exercise (Wang et al., 2015; Ma et al., 2017). A reduced rate of hepatic and muscle glycogen break-down and a greater potential for fatty acid metabolism could maintain blood glucose level, and thus enhancing exercise capacity (Favier and Koubi, 1988); (3) Delaying the accumulation of metabolites: With the accumulation of BUN and BLA, the pH in muscle tissue and blood reduced, which could obstruct the transmission of excitation at neuromuscular junctions, reduce the maximum tension and sustainability of muscle tissue, and hinder the process of sugar supply. PGC increased the LDH activity and the glycogen levels and retarded the accumulation of BUN and BLA (Oh et al., 2015; Delgado et al., 2019); (4) Promotion of mitochondrial function: SDH is a key enzyme associated with the regulation of the tricarboxylic acid cycle, catalyzing the synthesis of ATP. In addition, Na⁺-K⁺-ATPase and Ca²⁺-Mg²⁺-ATPase are crucial enzymes to degrade ATP. NRF-1 and TFAM are positive regulators of transcription. PGC improved SDH, Na⁺-K⁺-ATPase, and Ca²⁺Mg²⁺-ATPase activities. PGC enhanced the mRNA expression of NRF-1 and TFAM and increased the mtDNA content, and thereby enhancing mitochondrial function and producing more ATP for energy supplementation (Delgado et al., 2019); (5) Neuroprotection and antiapoptosis: PGC had a protective effect against MPTP-induced apoptosis in the mouse substantial nigra. This anti-apoptotic effect of PGC may be attributed to enhanced expression of Bcl-2 and Bcl-xL, reduced expression of bax and nitric oxide synthase, and inhibited activation of caspase-3 (Radad et al., 2006); (6) Regulation of neurotransmitter disorder: PGC decreased GABA and 5-HT levels, thereby increasing central nervous system excitability. PGC decreased the activity of acetylcholinesterase, maintained normal Ach and norepinephrine levels in cholinergic neurons, and enhanced the level of DA in the hippocampus (Feng et al., 2009b; Chen and Li, 2011).

CONCLUSIONS
The findings of present study demonstrated that PGC exerted anti-fatigue function, mainly through antioxidant stress, regulation of carbohydrate metabolism, delaying the accumulation of metabolites, promotion of mitochondrial function, neuroprotection and antiapoptosis, and regulation of neurotransmitter disorder. And the findings supported, at least to an extent, the use of PGC for fatigue.

AUTHOR CONTRIBUTIONS
Study conception and design: YL/G-QZ. Acquisition, analysis and/or interpretation of data: T-YJ/P-QR/H-YL/P-PZ/G-QZ/YL Final approval and overall responsibility for this published work: YL/G-QZ.

FUNDING
This study was supported by a grant from the National Natural Science Foundation of China (81973657/H2902); priority speciality of integrative brain diseases, the second affiliated hospital of Wenzhou Medical University, Wenzhou China (2016).

REFERENCES
Alraek, T., Lee Ms Fau - Choi, T.-Y., Choi Ty Fau - Cao, H., Cao H Fau - Liu, J., and Liu, J. (2011). Complementary and alternative medicine for patients with chronic fatigue syndrome: a systematic review. Complementary Altern. Med. 11, 87–98. doi: 10.1186/1472-6882-11-87
Angelis, C. D., De Drazen, J. M., Frizelle, F. A., Charlotte, H., John, H., Richard, H., et al. (2006). Is this clinical trial fully registered? A statement from the International Committee of Medical Journal Editors. Am. J. Ophthalmol. 140, 567–567. doi: 10.1016/j.ajo.2005.07.004
Arring, N. M., Millstine, D., Marks, L. A., and Nail, L. M. (2018). Ginseng as a Treatment for Fatigue: A Systematic Review. J. Altern. Complementary Med. 24, acm.2017.0361. doi: 10.1089/acm.2017.0361
Bach, H. V., Kim, J., Myung, S. K., and Cho, Y. A. (2016). Efficacy of Ginseng Supplements on Fatigue and Physical Performance: a Meta-analysis. J. Korean Med. Sci. 31, 1879–1886. doi: 10.3346/jkms.2016.31.12.1879

Feng, C. Y., Pan, H. S., Zhao, Z. M., and Wen, X. (2010b). The Effects of Ginsenoside RB1 and Ginsenosides on the Biochemical Index of Rat Skeletal Muscle with Exercise-induced Fatigue. J. Nanjing Institute Phys. Edu. (Natural Sci.) 9, 24–25+44. doi: 10.15877/j.cnki.syfjx.2011.19.071

Fukuda, K., Straus SE, Hickie, I., Sharpe, M. C., Dobbins, J. G., and Komaroff, A. (1994). The chronic fatigue syndrome: a comprehensive approach to its definition and study. Int. Chronic Fatigue Syndrome Study Group 121, 953–959. doi: 10.7326/0003-4819-121-19941125-00009

Gal, M. L., Calabrese, P., and Strulzy, K. (1996). Pharmaton capsules in the treatment of functional fatigue: A double-blind study versus placebo evaluated by a new methodology. Phytother. Res. 10, 49–53. doi: 10.1002/(SICI)1099-1573(199602)10:1<49::AID-PTR772>3.0.CO;2-M

Gao, W. B., Mi, J., Qin, Q. J., Sun, J. H., Wu, W., Wang, S. M., et al. (2011). Anti-fatigue Effects of Ginseng and Its Processed Products. Chin. J. Exp. Tradit. Med. Formul. 17, 210–213. doi: 10.13422/j.cnki.cjtf.2011.19.071

Garcia, S. F., David, C., Clauser, S. B., Flynn, K. E., Thomas, L., Jin-Shei, L., et al. (2016). Standardizing patient-reported outcomes assessment in cancer clinical trials: a patient-reported outcomes measurement information system initiative. J. Clin. Oncol. 25, 5106–5112. doi: 10.1200/JCO.2007.12.2341

Hackman, D. G., and Redelmeier, D. A. (2006). Translation of research evidence from animals to humans. JAMA J. Am. Med. Assoc. 296, 1731–1732. doi: 10.1001/jama.296.14.1731

Hartz, A. J., Bentler, S., Noyes, R., Hoehns, J., Logemann, C., Sinfit, S., et al. (2004). Randomized controlled trial of Siberian ginseng for chronic fatigue. psychol. Med. 34, 51–61. doi: 10.1016/S0033-2917(03)008791

Higgins, J. P., and Green, S. (2011). Cochrane Handbook for Systematic Reviews of Interventions. Naunyn-Schmiedebergs Archiv Für Experiment. Pathol. Und Pharmacol. 5, 538.

Hwang, H., Kim, J., Park, J., Yun, H., Cheon, W. K., Kim, B., et al. (2014). Red ginseng treatment for two weeks promotes fat metabolism during exercise in mice. Nutrients, 1874–1885. doi: 10.3970/nm051874

Hyeong-Geuk, K., Jung-Hyo, C., Sa-Ra, Y., Jin-Seok, L., Jong-Min, H., Nam-Hun, L., et al. (2013). Antifatigue effects of Panax ginseng C.A. Meyer: a randomised, double-blind, placebo-controlled trial. PLoS One 8, e61271. doi: 10.1371/journal.pone.0061271

Jason, L. A., Evans, M., Brown, M., and Porter, N. (2010). What is fatigue? Pathological and nonpathological fatigue. Am. Acad. Phys. Med. Rehabil., 2, 327–331. doi: 10.1016/j.pmrm.2010.03.028

Jones, F. M., Maloney, E. M., Boneva, R. S., Boneva, R. S., Jones, A. B., and Reeves, W. C. (2007). Complementary and alternative medical therapy utilization by people with chronic fatigue illnesses in the United States. Complement. Altern. Med. 7, 12–22. doi: 10.1186/1472-6882-7-12

Kahan, B. C., Rehal, S., and Cro, S. (2015). Blinded Outcome Assessment Was Infrequently Used and Poorly Reported in Open Trials. PloS One 10 (6), e0131926. doi: 10.1371/journal.pone.0131926

Ki Sung, K., Takako, Y., Hyun Young, K., and Jeong Hill, P. (2006). Study on the nitric oxide scavenging effects of ginseng and its compounds. J. Agric. Food Chem. 54, 2558. doi: 10.1021/jf0529520

Kilkenny, C., Browne, W., Cuthill, I., Emerson, M., and Altman, D. (2012). Improving bioscience research reporting: The ARRIVE guidelines for reporting animal research. Veterinary Clin. Pathol. 41, 27–31. doi: 10.1111/j.1939-165X.2012.00418.x

Kim, S. N., Ha, Y. W., Shin, H., Son, S. H., Wu, S. J., and Kim, Y. S. (2007). Simultaneous quantification of 14 ginsenosides in Panax ginseng C.A. Meyer (Korean red ginseng) by HPLC-ELSD and its application to quality control. J. Pharmaceut. Biomed. Anal. 45, 164–170. doi: 10.1016/j.jpba.2007.05.001

Kim, K. M., Kim, M. J., Song, S. W., Cho, D. Y., Park, K. C., Yang, S. W., et al. (2016). Efficacy and Safety of “URSA Complex” in Subjects with Physical Fatigue: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial. J. Clin. Med. 15, 239–134. doi: 10.4103/0366-6999.137432

Klimas, N. G., Broderick, G., and Fletcher, M. A. J. (2012). Biomarkers for chronic fatigue. Brain. Behav. Immun. 26, 1202–1210. doi: 10.1016/j.bbi.2012.04.012
systemic lupus erythematosus. Arch. Neurol. 46, 1121–1123. doi: 10.1001/archneur.1989.00520460110222

Lee, N., Lee, S. H., Yoo, H. R., and Yoo, H. S. (2016). Anti-Fatigue Effects of Enzyme-Modified Ginseng Extract: A Randomized, Double-Blind, Placebo-Controlled Trial. J. Altern. Complement Med. 22, acm.2016.0057. doi: 10.1089/acm.2016.0057

Lewis, J. A., and Machin, D. (1993). Intention to treat—which should use ITT? Br. J. Cancer 68, 647–650. doi: 10.1038/bjc.1993.402

Lewis, G., and Wessely, S. (1992). The epidemiology of fatigue: more questions than answers. J. Epidemiol. Community Health 46, 92–97. doi: 10.1136/jech.46.2.92

Li, D., Ren, J. W., Zhang, T., Liu, R., Wu, L., Dua, Q., et al. (2018). Anti-fatigue effects of small-molecule oligopeptides isolated from Panax quinquefolium L. in mice. Food Funct. 9, 8–16. doi: 10.1039/c6fo01658a

Li, P. J., Zhang, T., Wang, Y. X., and Wang, F. (2009). The study of anti-fatigue action of pseudo-ginsenoside QQ on exhaustive mouses. Chin. J. Lab. Diagn. 13, 869–871. doi: 10.3969/j.issn.1007-4287.2009.07.006

Liu, N., Liu, K., Liu, B. C., Wu, X. Q., Ding, Y., Xie, W., et al. (2015). Study on Anti-fatigue Effect of Ginsenoside on Mice. Guangjing J. Chin. Med. 30, 1867–1869. doi: 10.3969/j.issn.1003-8914.2015.09.022

Liu, L. C. (2016). Ginsenoside Rgl1 Has Impacts Exhaustive Exercise Rats of Skeletal Muscle and Brain Tissue Carbohydrated Protein Content(Master’s) (Human Normal University). Available at: http://cdmd.cnki.com.cn/Article/CDMD-1016085811.htm

Ma, G. D., Chiu, C. H., Hou, Y. J., Hou, C. W., Chen, Y. M., and Huang, C. C. (2017). Changbai Mountain Ginseng (Panax ginseng C.A. Mey) Extract Supplementation Improves Exercise Performance and Energy Utilization and Decreases Fatigue-Associated Parameters in Mice.LID - E237 [pii] LID - 10.3390/Molecules22020237.

McNair, D. M., Lorr, M., and Droppleman, L. F. (1992). Profile of Mood States Manual. San Diego: Educational and Industrial Testing Service.

Moher, D., Schulz, K. F., and Altman, D. G. (2005). The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Br. J. Psychiatry 187, 36–41. doi: 10.1192/ije.2009.03.057

Pan, H. S., Zhang, Z. H., Zhao, Z. M., and Feng, Y. C. (2010b). Effects of 20(S)-Protopanaxadiol and 20(S)-Protopanaxatriol in Mice. Zhongxiyi Jiehe Zazhi Chin. J. Integrated Tradit. Western Med. 13, 1365.2009.03.057. doi: 10.1055/s-2008-1074929

Song, X. T., Zhang, J. Y., Meng, L. Y., Gao, F., Wu, X. G., and Zhang, K. (2013). Effect of ginseng three alcohol saponin on blood glucose, blood lactic acid and blood urea nitrogen in sports fatigue rats. Chin. J. Public Health Eng. 12, 359–361. doi: 10.2855/j.isleni.4199.2013.05.0359

Stewart, L. A., Clarke, M., Rovers, M., Riley, R. D., Simmonds, M., Stewart, G., et al. (2015). Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA 313, 1657–1665. doi: 10.1001/jama.2015.3656

Sun, B. S., Gu, L. J., Fang, Z. M., Wang, C., Wang, Z., Lee, M. R., et al. (2009). Simultaneous quantification of 19 ginsenosides in black ginseng developed from Panax ginseng by HPLC–ELSD. J. Pharmaceut. Biomed. Anal. 50, 15–22. doi: 10.1016/j.jpba.2009.03.025

Twisk, F. A.-O., and Corsius, L. (2018). Cognitive-behavioural therapy for chronic fatigue syndrome: no efficacious nor safe. Br. J. Psychiatry, 211, 259–261. doi: 10.1192/bjp.2018.136

Voshaar, M. A. H., Oude Klooster, P. M., Ten Christina, B., Vonkeman, H. E., van den Born, J., Lim, J., et al. (2015). Assessment of Fatigue in Rheumatoid Arthritis: A Psychometric Comparison of Single-item, Multisitem, and Multidimensional Measures. J. Rheumatol. 42, 413–420. doi: 10.3899/jrheum.140389

Wang, J., Li, S. S., Fan, Y. Y., Chen, Y., Liu, D., Cheng, H. R., et al. (2010). Anti-fatigue activity of the water-soluble polysaccharides isolated from Panax ginseng C.A. Meyer. J. Ethnopharmacol. 130, 421–423. doi: 10.1016/j.jep.2010.05.027

Wang, J., Sun, C., Zheng, Y., Zheng Y., Pan, H., Pan, H., et al. (2013). The effective mechanism of the polysaccharides from Panax ginseng on chronic fatigue syndrome. Arch. Pharmacal. Res. 37, 530–538. doi: 10.1007/s12272-013-0235-9

Wang, Y., Ma, L., Pei, S. P., and Cai, D. L. (2015). Experimental study on Anti-fatigue Effect of ginsenoside Rg1 on fatigue resistance and SIRT1 in aged rats. Food Funct, 16. doi: 10.1039/c7fo01658a

Xue, C. L., Gu, Y., Wang, W. W., Lu, L., Fu, D. L., Liu, A. J., et al. (2013). Efficacy and safety of Suanzaoren decoction for primary insomnia: a systematic review of randomized controlled trials. BMC Complement. Altern. Med. 13, 1–12. doi: 10.1186/1472-6822-13-18

Yao, J. C. (2016). Efficacy of ginsenoside on anti-fatigue in mice. Clin. J. Chin. Med. 8, 9–10. doi: 10.3969/j.issn.1674-052X.2013.02.005

Yennurajalingam, S., Tannir, N. M., Williams, J. L., Lu, Z., Hess, K. R., Fischbein, S., et al. (2017). A Double-Blind, Randomized, Placebo-Controlled Trial of Panax Ginseng for Cancer-Related Fatigue in Patients With Advanced Cancer. J. Natl. Compr. Cancer Netw. 15, 1111–1120. doi: 10.6004/jnccn.2017.0149

Zhang, J. Y., Dai, J. L., Lv, J., and Jia, T. Z. (2014). Compare Ginseng and Its Processed Products’ Effect on Mice’s Hypoxia and Anti-Fatigue Function. Liaoning J. Tradit. Chin. Med. 41, 1040–1042. doi: 10.13192/jjp.2010.1719.2014.05.090

Zheng, Q., Bao, X. Y., Zhu, P. C., Tong, Q., Zheng, G. A.-O., and Wang, Y. A.-O. (2017). Ginsenoside Rb1 for Myocardial Ischemia/Reperfusion Injury: Systemic lupus erythematosus. Arch. Neurol. 46, 1121–1123. doi: 10.1001/archneur.1989.00520460110222
Preclinical Evidence and Possible Mechanisms. *Oxid. Med. Cell. Longevity* 2, 1–14. doi: 10.1155/2017/6313625
Zheng, Q., Zhu, J. Z., Bao, X. Y., Zhu, P. C., Tong, Q., Huang, Y. Y., et al. (2018). A Preclinical Systematic Review and Meta-Analysis of Astragaloside IV for Myocardial Ischemia/Reperfusion Injury. *Front. Physiol.* 9, 795. doi: 10.3389/fphys.2018.00795
Zhou, X. L., Xu, M. B., Jin, T. Y., Rong, P. Q., Zheng, G. Q., and Lin, Y. (2019). Preclinical Evidence and Possible Mechanisms of Extracts or Compounds from Cistanches for Alzheimer’s Disease. *Aging Dis.* 10, 1075. doi: 10.14336/AD.2018.0815-1

**Conflict of Interest:** The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2020 Jin, Rong, Liang, Zhang, Zheng and Lin. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.